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IMPORTANCE Hypertriglyceridemia is the most frequent and limiting adverse effect of
bexarotene therapy in cutaneous T-cell lymphoma (CTCL). Despite standard prophylactic
measures, there is a wide variability in the severity of this complication, which could be
associated with both genetic and environmental factors.
OBJECTIVES To analyze the association between genetic polymorphisms of apolipoprotein
genes APOA5, APOC3, and APOE and the severity of hypertriglyceridemia during bexarotene
therapy and to optimize patient selection for bexarotene therapy based on adverse effect
profile.
DESIGN, SETTING, AND PARTICIPANTS This case series study was conducted in 12 university
referral hospitals in Spain from September 17, 2014, to February 6, 2015. One hundred
twenty-five patients with a confirmed diagnosis of CTCL who had received bexarotene
therapy for at least 3 months were enrolled. Nine patients were excluded owing to missing
analytic triglyceride level data, leaving a study group of 116 patients. Data on demographic
and cardiovascular risk factor were collected, and a complete blood analysis, including lipid
profile and genetic analysis from a saliva sample, was performed.
MAIN OUTCOMES AND MEASURES Primary outcomes were the maximal triglyceride levels
reported in association with the minor alleles of the polymorphisms studied.
RESULTS Among 116 patients, the mean (SD) age was 61.2 (14.7) years, 69 (59.5%) were men,
and 85 (73.2%) had mycosis fungoides, the most prevalent form of CTCL. During bexarotene
therapy, 96 patients (82.7%) experienced hypertriglyceridemia, which was severe or extreme
in 8 of these patients (8.3%). Patients who carried minor alleles of the polymorphisms did not
show significant differences in baseline triglyceride concentrations. After bexarotene
treatment, carriers of at least 1 of the 2 minor alleles of APOA5 c.-1131T>C and APOC3
c.*40C>G showed lower levels of triglycerides than noncarriers (mean [SD], 241.59 [169.91] vs
330.97 [169.03] mg/dL, respectively; P = .02).
CONCLUSIONS AND RELEVANCE These results indicate that the screening of APOA5 and
APOC3 genotypes may be useful to estimate changes in triglyceride concentrations during
bexarotene treatment in patients with CTCL and also to identify the best candidates for
bexarotene therapy based on the expected adverse effect profile.
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B exarotene, a synthetic retinoid and member of a sub-class of retinoids called rexinoids,1 was approved by theUS Food and Drug Administration for the treatment of
cutaneous T-cell lymphoma (CTCL) in 1999 and licensed in
2002 in Europe for the treatment of patients with advanced
CTCL (stages IIB-IVB) refractory to at least 1 systemic treat-
ment. Bexarotene has also been shown to be an effective and
safe treatment for refractory early-stage CTCL (stages I-IIA).1-4
Dyslipidemia, mainly hypertriglyceridemia, and central hy-
pothyroidism are the most common adverse effects of bexaro-
tene. These effects are dose-related and reversible when drug
treatment is discontinued.5-7 This bexarotene-induced hyper-
triglyceridemia may be severe, and triglyceride levels of 991.15
mg/dL or greater (reference threshold, <160 mg/dL; to con-
vert to millimoles per liter, multiply by 0.0113) can increase the
risk of pancreatitis.8 Guidelines recommend the use of pro-
phylactic hypolipemic therapy from 1 week before beginning
bexarotene treatment to maintain triglyceride levels less than
486.73 mg/dL in the general population and less than 309.73
mg/dL in patients with known cardiovascular disease.1 It is rec-
ommended to start that treatment with a fibrate, usually fe-
nofibrate, and simultaneously or later add a statin or ω-3 fatty
acids if there is poor control of the dyslipemia.1,7,9
Despite these prophylactic measures and strict lifestyle
control, hypertriglyceridemia often cannot be avoided, and it
is the principal cause of bexarotene therapy discontinuation.
Risk factors for development of severe hypertriglyceridemia
after bexarotene treatment have not been well defined. Envi-
ronmental and genetic factors are both known to alter plasma
triglyceride levels in the general population.10 Triglyceride lev-
els vary widely among and within individuals during bexaro-
tene treatment. Thus, it would be of interest to identify ge-
netic factors associated with the risk of developing severe
hypertriglyceridemia during bexarotene therapy. In the gen-
eral population, genes that code for apolipoprotein A5 (ApoA5),
ApoC3, and ApoE are consistently directly associated with
triglyceride concentrations. The minor allele of the APOA5
c.-1131T>C and c.56G>C single-nucleotide polymorphism, the
APOC3 c.*40C>G polymorphism, and the APOE c.388T>C and
c.526C>T polymorphisms are associated with higher triglyc-
eride levels and also with risk for coronary artery disease, meta-
bolic syndrome, and stroke.11-15
The aim of this study was to analyze the association of
these genetic polymorphisms of APOA5 (OMIM 606368),
APOC3 (OMIM 107720), and APOE (OMIM 107741) with the
severity of bexarotene-associated hypertriglyceridemia in
patients with CTCL.
Methods
This retrospective, observational, noninterventionist, multi-
center case series study was conducted in 12 Spanish univer-
sity hospital dermatology departments from September 17,
2014, to February 6, 2015. The study was approved by the
Clinical Research Ethics Committee of Bellvitge University Hos-
pital, Barcelona, Spain, as the reference center and thereafter
from the medical ethics committees of the remaining hospi-
tals (Hospital Universitari de Bellvitge, Barcelona; Hospital Uni-
versitario Nuestra Señora de la Candelaria, Santa Cruz de Tener-
ife; Complejo Hospitalario Universitario Insular Materno-
Infantil, Las Palmas de Gran Canaria; Hospital Universitario
Virgen del Rocio, Sevilla; Hospital General Universitario de
Valencia, Valencia; Hospital Clínic de Barcelona, Barcelona;
Hospital Universitario de Basurto, Bilbao; Hospital del Mar, Bar-
celona; Hospital Universitario de Salamanca, Salamanca; Hos-
pital Nuestra Señora del Prado, Talavera; Hospital Arnau de
Vilanova, Lleida; and Hospital Universitario 12 de Octubre, Ma-
drid). Participants provided written informed consent accord-
ing to the Declaration of Helsinki16 protocols.
Study Design and Data Collection
Patients eligible for inclusion were 18 years or older, had a con-
firmed diagnosis of CTCL, and had been treated for at least 3
months with bexarotene. To prevent selection bias, the inves-
tigator at each center obtained the list of living patients with
CTCL and ordered them in reverse order of date of diagnosis,
starting from the patient with the most recent diagnosis. Pa-
tients with severe renal or hepatic failure or who were being
treated with drugs with a known hypertriglyceridemic ad-
verse effect were excluded. Participants were interviewed to
collect information on demographic characteristics, cardio-
vascular risk factors, and lifestyle habits. The following clini-
cal findings were recorded: age, sex, weight, height, and body
mass index (BMI) (calculated as weight in kilograms divided
by height in meters squared), smoking and alcohol consump-
tion, diabetes, hypertension, previous dyslipidemia, physi-
cal exercise and dietary habits, histologic subtype, initial CTCL
stage at diagnosis and stage at the beginning of bexarotene
treatment, duration of bexarotene treatment, and response to
the drug.
For the evaluation of clinical response to bexarotene, all
participating centers uniformly used the standard end points
proposed by Olsen et al.17 A saliva sample was collected dur-
ing the medical visit for genetic study. Baseline analytic data,
including renal and liver function, lipid profile, complete blood
cell count, and thyroid hormone levels at 1 and 3 months af-
ter initiation of bexarotene treatment, were collected retro-
spectively. All pharmacologic treatment of these patients was
provided as part of usual clinical practice.18 Standard recom-
mendations for bexarotene use in CTCL established that pa-
tients should start at a low dose and subsequently increase it
Key Points
Question Do APOA5, APOC3, and APOE polymorphisms play a
role in the severity of hypertriglyceridemia in patients receiving
bexarotene therapy for cutaneous T-cell lymphoma?
Findings In this case series study of 116 patients with cutaneous
T-cell lymphoma who underwent at least 3 months of bexarotene
treatment, those who carried the minor alleles of APOA5
c.-1131T>C or APOC3 c.*40C>G experienced less severe
hypertriglyceridemia.
Meaning Screening for APOA5 and APOC3 polymorphisms may
help physicians who treat patients with cutaneous T-cell
lymphoma identify the best candidates for bexarotene treatment.
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up to the maximum recommended dose of 300 mg/m2/d based
on the patient’s tolerance and the level of hypertriglyceride-
mia. In our study, these recommendations were uniformly ad-
opted in every participating center. Thus, all patients were
treated with bexarotene at an initial dose of 150 mg/m2/d,
which was subsequently titrated to full doses of 300 mg/
m2/d after 1 to 3 months of therapy depending on tolerance.1,6,7
They also had received prophylactic hypolipidemic therapy
from 1 week before the beginning of bexarotene treatment
and 50 μg/d of levothyroxine sodium from the beginning of
treatment, both continuing throughout bexarotene treat-
ment. The investigator at each center collected the clinical
and analytic data and thereafter provided those to a con-
tract research organization specifically designed for the
study. All data were encrypted and rendered anonymous so
that the information collected in the centralized database
could not identify the patients in the study. The entire pro-
cedure was strictly accomplished with the requirements of
confidentiality pursuant to Spain’s Organic Law 15/1999 on
Protection of Personal Data.
Genetic Studies
Gene variant analysis was performed in the clinical labora-
tory of Bellvitge University Hospital. Saliva samples were col-
lected, preserved, and transported in saliva-collection tubes
(Oragene; DNA Genotek). DNA was extracted from saliva in an
automated system (Maxwell16, model MX3031; Promega
Corporation). All samples were codified and anonymized, and
only the investigators responsible for the laboratory had
access to them.
We studied the presence of the minor allele vs homozygo-
sis for the major allele for the following gene variants: c.-
1131T>C (rs662799, APOA5); c.56G>C (rs3135506, APOA5);
c.*40C>G (rs5128, APOC3); c.388T>C (rs429358, APOE*E4);
c.526C>T (rs7412, APOE*E2). All were genotyped using allele-
specific TaqMan probes (Life Technologies) in a real-time
polymerase chain reaction system (iQ5; BioRad).
Statistical Analysis
All statistical analyses were performed using SPSS, version 19
statistical software (SPSS Inc). Deviations from Hardy-
Weinberg equilibrium were assessed using the χ2 test. Cat-
egorical and ordinal variables are presented as frequencies and
percentages; means and SDs are used for continuous vari-
ables. The qualitative variables were analyzed using the χ2 or
Fisher exact test and the quantitative variables using the paired,
2-tailed t test. To analyze the lipid profile data, the maximal
lipid value for the individual patient during follow-up was reg-
istered. Continuous variables that were not normally distrib-
uted were log transformed to achieve normal distribution
before fitting statistical models. To analyze which variables
were associated with maximal triglyceride concentrations
during bexarotene therapy, we used a stepwise multiple lin-
ear regression model with the variable log–maximal triglyc-
eride level as the dependent variable and log–baseline triglyc-
eride level, age, sex, BMI, and presence of minor alleles of each
polymorphism as risk factors. Statistical significance was set
at 2-sided P < .05.
Results
One hundred twenty-five patients met the inclusion criteria.
Nine were subsequently excluded because they had missing
analytic triglyceride level data. Therefore, 116 patients consti-
tuted the study group. Table 1 summarizes participants’ base-
line and disease characteristics. Mean age ranged from 34 to
88 years, and there was a male prevalence (69 [59.5%]). Mean
(SD) BMI was 26.9 (4.5), and 18 of the 116 patients (15.5%) were
obese (BMI >30). In our series, classic mycosis fungoides was
the most prevalent form of CTCL, with 85 patients (73.2%) hav-
ing this diagnosis. We found a predominance of advanced-
stage disease (IIB-IVB) (63 patients [54.3%]) at the time of
bexarotene treatment. After bexarotene treatment, 37 (31.9%)
showed complete response, 61 (52.6%) had partial response,
15 (12.9%) remained with stable disease, and 3 (2.6%) had
lymphoma progression. Thus, the overall response rate (com-
plete response + partial response) was 84.5% and the overall
control rate (complete response + partial response + stable dis-
ease) was 97.4%. Patients were treated with bexarotene for a
mean of 33 months (range, 3-140 months). As bexarotene
therapy was discontinued, we observed clinical progression
of the disease in 19 patients (16.4%).
Table 1. Clinical and Demographic Information of 116 Patients With CTCL
Characteristic No. (%)
Age, mean (SD) y 61.2 (14.7)
Male sex 69 (59.5)
BMI, mean (SD) 26.9 (4.5)
Cigarette smoker 32 (28.8)




Classic mycosis fungoides 85 (73.2)
Folliculotropic mycosis fungoides 22 (19.0)
Sézary syndrome 9 (7.8)
CTCL stage at diagnosis
I 69 (59.5)
IIA/IIB 4 (3.4)/22 (18.9)
III 14 (12.1)
IVA/IVB 6 (5.2)/1 (0.9)
CTCL stage at start of bexarotene treatment
I 36 (31.0)
IIA/IIB 17 (14.7)/17 (14.7)
III 24 (20.6)
IVA/IVB 18 (15.6)/4 (3.4)
Bexarotene response
Partial response 61 (52.9)
Complete response 37 (31.9)
Stable disease 15 (12.9)
Disease progression 3 (2.6)
Abbreviations: BMI, body mass index (calculated as weight in kilograms divided
by height in meters squared); CTCL, cutaneous T-cell lymphoma.
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Blood Lipid Analysis
Before bexarotene treatment, 83 of the 116 patients (71.5%) had
normal triglyceride levels. Following the accepted recommen-
dations, 112 patients (96.6%) initiated hypolipidemic therapy
before bexarotene, with 99 (85.3%) receiving fibrates as the ini-
tial prophylactic lipid-lowering treatment. During bexaro-
tene treatment, 96 patients (82.7%) developed hypertriglyc-
eridemia. According to the Adult Treatment Panel III
guidelines,18 the hypertriglyceridemia was classified as bor-
derline (150.44-194.69 mg/dL) in 12 patients (12.9%), high
(194.69-495.58 mg/dL) in 53 (55.2%), very high (>495.58 mg/
dL) in 23 (23.9%), and severe or extreme (≥991.15 mg/dL) in
8 (8.3%).
We observed statistically significant reductions in mean
(SD) levels before and 2 analytic data points after bexarotene
treatment in levels of thyrotropin (3.6 [15.1], 1.0 [2.6], and 1.9
[10.1] mIU/L; P = .02), free thyroxine (1.36 [1.72], 0.98 [0.99],
and 1.04 [0.99] ng/dl; P < .001), leukocytes (7000 [2800], 6100
[2300], and 6100 [3000] cells/μL; P = .01), and high-density
lipoprotein cholesterol (54.05 [19.31], 34.75 [19.31], and 0.9
[19.31] mg/dL; P < .001) and a significant increase in levels of
creatinine (0.89 [0.24], 0.95 [0.27)], and 0.95 [0.27] mg/dL;
P = .009); platelets (248.2 [68.1], 272.12 [75.9], and 271.9
[84.5] × 103/L; P = .02); total cholesterol (204.63 [40.54];
250.97 [57.92], and 243.24 [65.64]; P < .001); and low-
density lipoprotein cholesterol (123.55 [34.75], 158.30 [54.05],
and 142.86 [57.92]; P < .001). (To convert the level of free
thyroxine to picomoles per liter, multiply by 12.871; leuko-
cytes to cells ×109/L, multiply by 0.001; high-density and low-
density lipoprotein and total cholesterol to millimoles per
liter, multiply by 0.0259; creatinine to micromoles per liter,
multiply by 88.4; and platelets to cells ×109/L, multiply by 1.0.)
There were no statistically significant differences in glucose,
liver profile, or hematocrit levels.
Genetic Studies
Genetic polymorphism frequencies and baseline characteris-
tics are described in Table 2. The genotype distribution was
in Hardy-Weinberg equilibrium. By dividing number of mi-
nor alleles by number of total alleles and multiplying the quo-
tient by 100, we obtained similar allelic frequencies of the
minor allele in each gene, ranging from APOA5 c.-1131T>C as
the most prevalent (9.5%) to the APOA5 c.56G>C as the least
prevalent (6.9%). These frequencies did not deviate from pre-
vious data of the general white population, according to the
Exome Aggregation Consortium database, version 1.0.19 We ob-
served a significant difference in genotype frequency be-
tween men and women in the APOA5 c.-1131T>C polymor-
phism (65.3% men vs 34.7% women among TT carriers vs 33.3%
men vs 66.7% women among TC+CC carriers; P = .007) and in
age in the APOA5 c.56G>C polymorphism (62.6 vs 51.2 years
among TT carriers vs TC+CC carriers; P = .004) and APOE
c.526C>T polymorphism (59.8 vs 68.1 years; P = .02). Mean (SD)
BMI was higher in carriers of APOE c.388 TT than in TC+CC car-
riers (27.3 [4.5] vs 24.9 [4.1]; P = .04). There were no signifi-
cant genotype-related differences in any other baseline char-
acteristics studied. Minor allele carriers showed lower total
cholesterol values after bexarotene treatment for variants
APOA5 c.-1131T>C, APOC3 c.*40C>G, and APOE c.526C>T,
achieving statistical significance in the APOA5 c.-1131T>C geno-
type (204.25 [42.47] mg/dL in TT carriers before treatment vs
203.09 [35.91] mg/dL in TC+CC carriers before treatment and
277.99 [42.86] mg/dL in TT carriers after treatment vs 248.65
[54.44] mg/dL in TC+CC carriers after treatment; P = .046). Tri-
glyceride concentrations before and after bexarotene admin-
istration in each genetic polymorphism are shown in Table 3.
At baseline, the minor allele carriers of all the genes except
APOA5 c.56G>C exhibited nonsignificantly higher plasma tri-
glyceride concentrations than noncarriers. After bexarotene
therapy, lower maximal triglyceride concentrations were seen
when the minor allele was present. After adjusting for the base-
line triglyceride level in every patient, for sex in APOA5 c.-
1131T>C, and for age in APOA5 c.56C>G and APOE c.526C>T,
the association between triglyceride level changes and these
polymorphisms was not statistically significant. However, we
grouped APOA5 c.-1131T>C (carriers vs noncarriers, mean 1 [SD]
adjusted maximal triglyceride level, 246.90 [172.57] vs 327.43
[169.91] mg/dL; P = .10) and APOC3 c.*40C>G (carriers vs non-
carriers, mean 1 [SD] adjusted maximal triglyceride level, 251.33
[172.57] vs 324.78 [171.68] mg/dL; P = .14) in a single variable,
defining those patients carrying at least 1 of the minor alleles
as carriers, and this association was significant for triglycer-
ide reduction for carriers vs noncarriers (mean [SD] adjusted
maximal triglyceride level, 241.59 [169.91] vs 330.97 [169.03]
mg/dL; P = .02).
We observed a significant association between the initial
triglyceride levels and their maximum increase during bexaro-
tene treatment. For that, we performed an explanatory re-
gression model of the log-maximal triglyceride, which showed
that the only significant statistic variable was log-baseline
triglyceride, accounting for 25% of the total variability (regres-
sion coefficient, 0.76 [95% CI, 0.51-1.01]; R2 = 0.253; P < .001).
The higher the baseline triglyceride concentration, the higher
the maximal triglyceride concentration reached during bexaro-
tene treatment.
Discussion
Cutaneous T-cell lymphoma is a rare disease with a small
prevalence. Bexarotene is an effective systemic therapy for
patients with advanced or refractory CTCL, but hypertriglyc-
eridemia, which was recorded in 82.7% of our study patients,
used to be a limiting adverse effect. In this study, we aimed to
evaluate the influence of several APO gene polymorphisms in
the severity of hypertriglyceridemia induced by bexarotene
therapy in patients with CTCL. The purpose of screening was
to identify ideal patient selection for bexarotene therapy
based on the adverse effect profile, not to identify those who
will respond from a therapeutic standpoint.
To our knowledge, this is the largest multicenter
study4,20,21 to date evaluating patients with treated with
bexarotene and the first focusing on triglyceride metabolism.
Our results showed that, according to what has been ob-
served in the general population,11-15 patients with CTCL who
carry the minor allele of APOA5 c.-1131T>C, c.56G>C, APOC3
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c.*40C>G, and APOE c.388T>C and c.526C>T polymorphisms
had nonsignificantly higher baseline triglyceride levels. How-
ever, after bexarotene treatment was introduced, we ob-
served that carriers of at least 1 of the minor alleles of APOA5
c.-1131T>C and APOC3 c.*40C>G showed a significantly less se-
vere increase in triglyceride concentration. In contrast, APOA5
c.56G>C and the 2 APOE variants studied seemed to have no
particular association with triglyceride concentrations dur-
ing bexarotene therapy. These results are in apparent contra-
diction to previous knowledge on the biological effects of such
Table 2. Genetic Polymorphism Frequencies and Baseline Characteristics of 116 Patients With CTCL
Characteristic by Genetic Polymorphism Genotype P Value
APOA5 c.-1131T>C TT TC + CC
Patients, No. (%) 95 (81.9) 20 + 1 (18.1)
Age, mean (SD), y 61.1 (14.9) 61.3 (13.8) .95
Men, No. (%) 62/33 (65.3/34.7) 7/14 (33.3/66.7) .007
Smoker, No. (%) 27 (29.3) 5 (26.3) .79
BMI, mean (SD) 26.7 (4.2) 27.3 (5.8) .61
TC level before treatment, mean (SD), mg/dL 204.25 (42.47) 203.09 (35.91) .93
TC level after treatment, mean (SD), mg/dL 277.99 (42.86) 248.65 (54.44) .046
TG level before treatment, mean (SD), mg/dL 138.94 (86.73) 149.56 (97.35) .61
APOA5 c.56G>C GG GC + CC
Patients, No. (%) 101 (87.1) 14 + 1 (12.9)
Age, mean (SD), y 62.6 (14.5) 51.2 (12.2) .004
Men, No. (%) 60 (59.4) 9 (60.0) .97
Smoker, No. (%) 28 (28.6) 4 (30.8) >.99
BMI, mean (SD) 26.6 (4.5) 28.5 (4.2) .14
TC level before treatment, mean (SD), mg/dL 205.02 (43.24) 198.07 (27.03) .55
TC level after treatment, mean (SD), mg/dL 273.36 (61.39) 272.59 (68.73) .96
TG level before treatment, mean (SD), mg/dL 143.36 (92.92) 120.35 (50.44) .34
APOC3 c.*40C>G CC CG + GG
Patients, No. (%) 98 (84.5) 16 + 2 (15.5)
Age, mean (SD), y 61.9 (14.7) 57.3 (14.4) .22
Men, No. (%) 59 (60.2) 10 (55.6) .71
Smoker, No. (%) 27 (28.1) 5 (33.3) .76
BMI, mean (SD) 27.0 (4.7) 25.9 (3.1) .34
TC level before treatment, mean (SD), mg/dL 203.86 (42.08) 206.95 (39.00) .78
TC level after treatment, mean (SD), mg/dL 275.68 (63.32) 259.46 (57.53) .32
TG level before treatment, mean (SD), mg/dL 134.51 (85.84) 174.34 (100.00) .08
APOE c.388T>C TT TC + CC
Patients, No. (%) 96 (82.8) 19 + 1 (17.2)
Age, mean (SD), y 61.9 (14.8) 57.6 (13.7) .24
Men, No. (%) 58 (60.4) 11 (55.0) .65
Smoker, No. (%) 26 (28.0) 6 (33.3) .65
BMI, mean (SD) 27.3 (4.5) 24.9 (4.1) .04
TC level before treatment, mean (SD), mg/dL 202.70 (38.61) 211.20 (53.67) .41
TC level after treatment, mean (SD), mg/dL 271.43 (61.39) 281.85 (67.95) .49
TG level before treatment, mean (SD), mg/dL 137.17 (83.19) 155.75 (112.39) .42
APOE c.526C>T CC CT + TT
Patients, No. (%) 97 (83.6) 17 + 2 (16.4)
Age, mean (SD), y 59.8 (14.6) 68.1 (12.9) .02
Men, No. (%) 58 (59.8) 11 (57.9) .88
Smoker, No. (%) 27 (29.3) 5 (26.3) .79
BMI, mean (SD) 26.9 (4.7) 26.3 (3.6) .56
TC level before treatment, mean (SD), mg/dL 206.18 (40.54) 194.59 (45.95) .28
TC level after treatment, mean (SD), mg/dL 275.68 (62.55) 260.23 (62.16) .33
TG level before treatment, mean (SD), mg/dL 140.71 (85.84) 143.36 (105.31) .91
Abbreviations: BMI, body mass index (calculated as weight in kilograms divided
by height in meters squared); TC, total cholesterol; TG, triglycerides.
SI conversion factors: To convert TC to millimoles per liter, multiply by 0.0259;
TG to millimoles per liter, multiply by 0.0113.
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polymorphisms in the general population. Previous studies have
observed that carrying APOA5 c.-1131T>C and APOA5 c.56G>C
minor alleles is associated with hypertriglyceridemia,22,23 thus
conferring a higher risk for coronary artery disease, stroke, and
metabolic syndrome.24
A complete explanation for our results is difficult to es-
tablish, but a different hypothesis could be considered. Kim
et al25 showed that the APOA5 c.-1131T>C minor allele may lead
to reduced ApoA-V concentration, with concomitantly re-
duced lipoprotein lipase activity, resulting in higher triglyc-
eride levels in the general population. Those authors also ob-
served that this association was reversed when triglyceride
concentrations were greater than 150 mg/dL. We believe that
a similar phenomenon may partially explain our results. How-
ever, we must acknowledge limitations for this hypothesis, be-
cause we did not specifically include ApoA-V concentrations
in our work and the implications of these observations in the
other apolipoprotein genotypes are unknown thus far.
Another possible explanation for our results could be re-
lated to the association of some APO polymorphisms with the
response to fenofibrate therapy. The recent Genetics of Lipid
Lowering Drugs and Diet Network (GOLDN) Study tested the
association between the APOA1/C3/A4/A5 gene cluster and the
lipid response to 3-week fenofibrate treatment.26 In that study,
the authors observed that the minor alleles of APOA5_S19W
(c.56G>C), APOA4_N147S (c.440G>A), APOC3_G34G (c.102T>C),
and APOC3_3U386 (c.*40G>C) were significantly associated
with an enhanced triglyceride response to fenofibrate treat-
ment. In addition, in another branch of the GOLDN study, the
association between tagged single-nucleotide polymor-
phisms (c.-1131T>C and c.56G>C) at APOA5 and triglyceride and
high-density lipoprotein cholesterol response to 3 weeks of fe-
nofibrate treatment was examined in a group of 791 partici-
pants. In that study, it was observed that the minor allele car-
riers of the polymorphism c.56G>C presented a greater
triglyceride level decrease and high-density lipoprotein cho-
lesterol level increase in response to fenofibrate treatment
compared with noncarriers.27,28 In another recent study (B.
Candás, doctoral thesis, Barcelona University, December 1,
2011) the APOA5 c.-1131T>C, APOA5 c.56G>C, APOC3 c*40C>G,
and APOE c.388T>C polymorphisms and their association with
fenofibrate response were investigated. In that work, carriers
of the c*40C>G of the APOC3 gene responded to fenofibrate
treatment up to 11% better than noncarriers. Because our pa-
tients were simultaneously treated with bexarotene and fe-
nofibrate, these observations are in agreement with our data.
We do not know the exact association of each polymorphism
with fenofibrate therapy response; further pharmacoge-
nomic studies are needed to address this question.
In addition to the genetic results, laboratory data obtained
in this study showed that a higher baseline triglyceride concen-
tration was associated with higher maximal triglyceride con-
centrations during bexarotene treatment regardless of genetic
polymorphisms. This association, not previously reported, could
help physicians assess which patients will experience more se-
vere hypertriglyceridemia.
Table 3. Triglyceride (TG) Concentrations Before and After Bexarotene Treatmenta
Genetic Polymorphism
TG Concentration, Mean (SD), mg/dL
P ValueNoncarriers Carriers
APOA5 c.-1131T>C
TG level before treatment 121.24 (143.36) 125.66 (161.06) .78
Maximal TG level after treatment 328.32 (188.50) 246.90 (188.50) .12
Adjusted maximal TG levelb 327.43 (169.91) 246.90 (172.57) .10
APOA5 c.56G>C
TG level before treatment 123.89 (148.67) 111.50 (130.09) .46
Maximal TG level after treatment 312.39 (190.27) 307.96 (188.50) .84
Adjusted maximal TG, mean (SD), mg/dLc 310.62 (173.45) 320.35 (176.11) .87
APOC3 c.*40C>G
TG level before treatment 117.70 (142.48) 147.79 (163.72) .08
Maximal TG level after treatment 315.04 (191.15) 292.92 (181.42) .70
Adjusted maximal TG leveld 324.78 (171.68) 251.33 (172.57) .14
APOE c.388T>C
TG level before treatment 121.24 (143.36) 128.32 (161.06) .62
Maximal TG level after treatment 311.50 (190.27) 311.50 (189.38) >.99
Adjusted maximal TG leveld 314.16 (172.57) 299.12 (172.57) .76
APOE c.526C>T
TG level before treatment 122.12 (145.13) 120.35 (153.98) .88
Maximal TG level after treatment 319.47 (189.38) 275.22 (191.15) .44
Adjusted maximal TG levelc 317.70 (172.57) 284.07 (174.34) .51
APOA5 c.1131T>C and/or APOC3 c.*40C>G
TG level before treatment 119.47 (144.25) 130.97 (155.75) .45
Maximal TG level after treatment 330.97 (192.04) 253.98 (176.99) .12
Adjusted maximal TG leveld 330.97 (169.03) 241.59 (169.91) .02
SI conversion factor: To convert TG to
millimoles per liter, multiply by
0.0113.
a The analyses were performed with
the natural logarithm of the
maximal TG level; however, the data
are shown as antilogarithm of the
mean and the SD for easier
comprehension. Two models have
been performed to analyze the main
variable (maximal TG levels):
one unadjusted and the other
adjusted for baseline TG levels and
for variables that had shown
significant differences in genotypes.
b Adjusted by sex and baseline TG
model.
c Adjusted by age and baseline TG
model.
d Adjusted by TG model.
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Our results also show that bexarotene is an effective treat-
ment for CTCL, with a high overall response rate (84.5%). These
data support the use of bexarotene for patients with refrac-
tory and advanced-stage CTCL. The response rate in our pa-
tients seems higher than would be expected based on previ-
ous reports.4,20,21 We believe the greater response rate could
be because almost 60% of our patients were in an early phase
of the disease (stage I), in whom the response rate to bexaro-
tene treatment is reported to be higher than for those in more
advanced stages, including tumoral or erythrodermic phases.
In a recent study, a Phase 3 Trial of Brentuximab Vedotin (SGN-
35) vs Physician’s Choice (Methotrexate or Bexarotene) in Par-
ticipants With CD30-Positive Cutaneous T-Cell Lymphoma
(ALCANZA),29 the results of that clinical trial comparing bren-
tuximab vedotin with physician’s choice (bexarotene or metho-
trexate) in CD30-positive CTCLs showed that overall re-
sponse rate lasting 4 months in the physician’s choice branch
was 16%. We believe that, again, these differences in re-
sponse could reflect that the number of patients with early-
stage disease in ALCANZA was lower than that of patients in
our series. In addition, all patients in the ALCANZA trial had
CD30-positive mycosis fungoides. Because there is no infor-
mation about earlier particular sensitivity to bexarotene in this
setting, we believe it is difficult to contrast the ALCANZA re-
sults with standard cases of mycosis fungoides in regular clini-
cal practice.
Limitations
The findings of the present study may help physicians assess
which patients will have a better lipid-profile response and,
consequently, which may have a bad outcome. However, the
sensitivity of these polymorphisms for anticipating bad out-
comes is not yet clear, and we cannot establish which pa-
tients will need to discontinue treatment or which will expe-
rience pancreatitis. More studies should be done to investigate
these questions.
Conclusions
Cutaneous T-cell lymphoma is a rare disease with a reported
annual incidence of about 6.4 to 9.6 cases per million people
in the United States.6 To our knowledge, this is the largest mul-
ticenter study to date evaluating patients with CTCL treated
with bexarotene and the first to focus on the role of genetic
polymorphisms in bexarotene-induced hypertriglyceride-
mia. Our results show that patients carrying at least 1 of the
minor alleles of APOA5 c.-1131T>C or APOC3 c.*40C>G are less
likely to experience severe hypertriglyceridemia. These data
suggest that APO polymorphism investigation could be help-
ful in the clinical evaluation of bexarotene-induced hypertri-
glyceridemia in patients with CTCL and in the identification
of the most suitable candidates for this therapy.
ARTICLE INFORMATION
Accepted for Publication: August 23, 2018.
Published Online: October 24, 2018.
doi:10.1001/jamadermatol.2018.3679
Author Affiliations: Cardiovascular Risk Unit,
Hospital Universitari de Bellvitge, IDIBELL,
Barcelona, Spain (Cabello, Pintó); Clinical Genetics
Laboratory, Hospital Universitari de Bellvitge,
IDIBELL, Barcelona, Spain (Alia); Dermatology
Department, Hospital Universitari de Bellvitge,
IDIBELL, Barcelona, Spain (Muniesa, Servitje);
Dermatology Department, Hospital Universitario
Nuestra Señora de la Candelaria, Santa Cruz de
Tenerife, Spain (Fernandez-de-Misa); Dermatology
Department, Complejo Hospitalario Universitario
Insular Materno-Infantil, Las Palmas de Gran
Canaria, Spain (Peñate); Dermatology Department,
Hospital Universitario Virgen del Rocio, Sevilla,
Spain (Morillo); Dermatology Department, Hospital
General Universitario de Valencia, Valencia, Spain
(Perez-Farriols); Dermatology Department,
Hospital Clínic, IDIBAPS, Barcelona, Spain (Estrach);
Dermatology Department, Hospital Universitario de
Basurto, Bilbao, Spain (Izu); Dermatology
Department, Hospital del Mar, IMIM, Barcelona,
Spain (Gallardo); Dermatology Department,
Hospital Universitario de Salamanca, Salamanca,
Spain (Román); Dermatology Department, Hospital
Nuestra Señora del Prado, Talavera, Spain
(Cervigón); Dermatology Department, Hospital
Arnau de Vilanova, Lleida, Spain (Ortiz-Brugues);
Dermatology Department, Hospital Universitario 12
de Octubre, Institute i+12, CIBERONC, Medical
School, University Complutense, Madrid, Spain
(Ortiz-Romero).
Author Contributions: Dr Cabello had full access to
all of the data in the study and takes responsibility
for the integrity of the data and the accuracy of the
data analysis; Dr Alia had full access to the genetic
study data and samples and takes responsibility for
the integrity of those data and the accuracy of the
data analysis.
Concept and design: Cabello, Pintó, Estrach, Izu,
Ortiz-Romero, Servitje.
Acquisition, analysis, or interpretation of data:
Cabello, Alia, Pintó, Muniesa, Fernandez-de-Misa,
Peñate, Morillo, Perez-Ferriols, Estrach, Izu,
Gallardo, Román, Cervigón, Ortiz Brugues, Servitje.
Drafting of the manuscript: Cabello, Pintó, Estrach,
Izu, Cervigón, Servitje.
Critical revision of the manuscript for important
intellectual content: All authors.
Statistical analysis: Cabello.
Obtained funding: Cabello, Pintó, Muniesa, Servitje.
Administrative, technical, or material support:
Cabello, Pintó, Muniesa, Peñate, Izu, Román.
Supervision: Cabello, Alia, Pintó,
Fernandez-de-Misa, Perez-Ferriols, Izu, Gallardo,
Ortiz-Romero, Servitje.
Conflict of Interest Disclosures: None reported.
Funding/Support: This study was supported EISAI
Co LTD.
Role of the Funder/Sponsor: The funder had no
role in the design and conduct of the study;
collection, management, analysis and
interpretation of the data; preparation, review, or
approval of the manuscript; and decision to publish
the manuscript for publication.
Additional Contributions: The authors thank the
physicians and patients for their valuable
contributions to this study. Emili Corbella,
Cardiovascular Risk Unit, Hospital Universitari de
Bellvitge-IDIBELL; CIBEROBN, assisted in the
statistical analyses of the manuscript. He was not
compensated for his work on this manuscript. The
members of Experior, CRO, contracted by IDIBELL
performed the tasks of protocol review,
commissioning, and coordination of the collection
and delivery of genetic samples to the genetic
testing center of IDIBELL.
REFERENCES
1. Scarisbrick JJ, Morris S, Azurdia R, et al. U.K.
consensus statement on safe clinical prescribing of
bexarotene for patients with cutaneous T-cell
lymphoma. Br J Dermatol. 2013;168(1):192-200.
doi:10.1111/bjd.12042
2. Panchal MR, Scarisbrick JJ. The utility of
bexarotene in mycosis fungoides and Sézary
syndrome. Onco Targets Ther. 2015;8:367-373.
3. Whittaker SJ, Marsden JR, Spittle M, Russell
Jones R; British Association of Dermatologists; U.K.
Cutaneous Lymphoma Group. Joint British
Association of Dermatologists and U.K. Cutaneous
Lymphoma Group guidelines for the management
of primary cutaneous T-cell lymphomas. Br J
Dermatol. 2003;149(6):1095-1107. doi:10.1111/j.1365
-2133.2003.05698.x
4. Quéreux G, Saint-Jean M, Peuvrel L, Brocard A,
Knol AC, Dréno B. Bexarotene in cutaneous T-cell
lymphoma: third retrospective study of long-term
cohort and review of the literature. Expert Opin
Pharmacother. 2013;14(13):1711-1721. doi:10.1517
/14656566.2013.810718
5. Trautinger F, Knobler R, Willemze R, et al. EORTC
consensus recommendations for the treatment of
mycosis fungoides/Sézary syndrome. Eur J Cancer.
2006;42(8):1014-1030. doi:10.1016/j.ejca.2006.01
.025
Research Original Investigation APOA5 and APOC3 Polymorphisms and Hypertriglyceridemia in Bexarotene-Treated CTCL
1430 JAMA Dermatology December 2018 Volume 154, Number 12 (Reprinted) jamadermatology.com
© 2018 American Medical Association. All rights reserved.
6. Wilcox RA. Cutaneous T-cell lymphoma: 2014
update on diagnosis, risk-stratification, and
management. Am J Hematol. 2014;89(8):837-851.
doi:10.1002/ajh.23756
7. Assaf C, Bagot M, Dummer R, et al. Minimizing
adverse side-effects of oral bexarotene in
cutaneous T-cell lymphoma: an expert opinion. Br J
Dermatol. 2006;155(2):261-266. doi:10.1111/j.1365
-2133.2006.07329.x
8. Lloret Linares C, Pelletier AL, Czernichow S, et al.
Acute pancreatitis in a cohort of 129 patients
referred for severe hypertriglyceridemia. Pancreas.
2008;37(1):13-2. doi:10.1097/MPA
.0b013e31816074a1
9. Cabello I, Servitje O, Corbella X, Bardés I, Pintó
X. Omega-3 fatty acids as adjunctive treatment for
bexarotene-induced hypertriglyceridaemia in
patients with cutaneous T-cell lymphoma. Clin Exp
Dermatol. 2017;42(3):276-281. doi:10.1111/ced.13044
10. Lewis GF, Xiao C, Hegele RA. Hypertriglycer-
idemia in the genomic era: a new paradigm. Endocr
Rev. 2015;36(1):131-147. doi:10.1210/er.2014-1062
11. Melegh BI, Duga B, Sümegi K, et al. Mutations of
the apolipoprotein A5 gene with inherited
hypertriglyceridaemia: review of the current
literature. Curr Med Chem. 2012;19(36):6163-6170.
doi:10.2174/0929867311209066163
12. Johansen CT, Kathiresan S, Hegele RA. Genetic
determinants of plasma triglycerides. J Lipid Res.
2011;52(2):189-206. doi:10.1194/jlr.R009720
13. Lamiquiz-Moneo I, Blanco-Torrecilla C, Bea AM,
et al. Frequency of rare mutations and common
genetic variations in severe hypertriglyceridemia in
the general population of Spain. Lipids Health Dis.
2016;15:82. doi:10.1186/s12944-016-0251-2
14. Zhao T, Zhao J. Association of the
apolipoprotein A5 gene -1131 T>C polymorphism
with fasting blood lipids: a meta-analysis in 37859
subjects. BMC Med Genet. 2010;11:120. doi:10.1186
/1471-2350-11-120
15. Dergunov AD. Apolipoprotein E genotype as a
most significant predictor of lipid response at
lipid-lowering therapy: mechanistic and clinical
studies. Biomed Pharmacother. 2011;65(8):597-603.
doi:10.1016/j.biopha.2011.04.003
16. World Medical Association. World Medical
Association Declaration of Helsinki: ethical
principles for medical research involving human
subjects. JAMA. 2013;310(20):2191-2194. doi:10
.1001/jama.2013.281053
17. Olsen EA, Whittaker S, Kim YH, et al;
International Society for Cutaneous Lymphomas;
United States Cutaneous Lymphoma Consortium;
Cutaneous Lymphoma Task Force of the European
Organisation for Research and Treatment of Cancer.
Clinical end points and response criteria in mycosis
fungoides and Sézary syndrome: a consensus
statement of the International Society for
Cutaneous Lymphomas, the United States
Cutaneous Lymphoma Consortium, and the
Cutaneous Lymphoma Task Force of the European
Organisation for Research and Treatment of Cancer.
J Clin Oncol. 2011;29(18):2598-2607. doi:10.1200
/JCO.2010.32.0630
18. Expert Panel on Detection, Evaluation, and
Treatment of High Blood Cholesterol in Adults.
Executive Summary of The Third Report of The
National Cholesterol Education Program (NCEP)
Expert Panel on Detection, Evaluation, And
Treatment of High Blood Cholesterol in Adults
(Adult Treatment Panel III). JAMA. 2001;285(19):
2486-2497. doi:10.1001/jama.285.19.2486
19. ExAC Browser (Beta)/Exome Aggregation
Consortium website. http://exac.broadinstitute
.org/. Accessed September 21, 2018.
20. Abbott RA, Whittaker SJ, Morris SL, et al.
Bexarotene therapy for mycosis fungoides and
Sézary syndrome. Br J Dermatol. 2009;160(6):
1299-1307. doi:10.1111/j.1365-2133.2009.09037.x
21. Väkevä L, Ranki A, Hahtola S. Ten-year
experience of bexarotene therapy for cutaneous
T-cell lymphoma in Finland. Acta Derm Venereol.
2012;92(3):258-263. doi:10.2340/00015555-1359
22. Pennacchio LA, Olivier M, Hubacek JA, Krauss
RM, Rubin EM, Cohen JC. Two independent
apolipoprotein A5 haplotypes influence human
plasma triglyceride levels. Hum Mol Genet. 2002;11
(24):3031-3038. doi:10.1093/hmg/11.24.3031
23. Talmud PJ, Hawe E, Martin S, et al. Relative
contribution of variation within the APOC3/A4/A5
gene cluster in determining plasma triglycerides.
Hum Mol Genet. 2002;11(24):3039-3046. doi:10
.1093/hmg/11.24.3039
24. Oliveira Sousa M, Alía P, Pintó X.
Apolipoprotein A5 gene: association with
triglyceride metabolism and cardiovascular disease
[in Spanish]. Med Clin (Barc). 2008;130(20):787-793.
doi:10.1157/13121105
25. Kim JY, Kim OY, Paik JK, Lee SH, Lee JH.
Association of apolipoprotein A-V concentration
with apolipoprotein A5 gene -1131T>C
polymorphism and fasting triglyceride levels. J Clin
Lipidol. 2013;7(2):94-101. doi:10.1016/j.jacl.2012.06
.002
26. Liu Y, Ordovas JM, Gao G, et al.
Pharmacogenetic association of the
APOA1/C3/A4/A5 gene cluster and lipid responses
to fenofibrate: the genetics of lipid-lowering drugs
and diet network study. Pharmacogenet Genomics.
2009;19(2):161-169. doi:10.1097/FPC
.0b013e32831e030e
27. Lai CQ, Arnett DK, Corella D, et al. Fenofibrate
effect on triglyceride and postprandial response of
apolipoprotein A5 variants: the GOLDN study.
Arterioscler Thromb Vasc Biol. 2007;27(6):1417-1425.
doi:10.1161/ATVBAHA.107.140103
28. Hegele RA, Pollex RL. Apolipoprotein A-V
genetic variation and plasma lipoprotein response
to fibrates. Arterioscler Thromb Vasc Biol. 2007;
27(6):1224-1227. doi:10.1161/ATVBAHA.107.144980
29. Prince HM, Kim YH, Horwitz SM, et al;
ALCANZA study group. Brentuximab vedotin or
physician’s choice in CD30-positive cutaneous T-cell
lymphoma (ALCANZA): an international,
open-label, randomised, phase 3, multicentre trial.
Lancet. 2017;390(10094):555-566. doi:10.1016
/S0140-6736(17)31266-7
APOA5 and APOC3 Polymorphisms and Hypertriglyceridemia in Bexarotene-Treated CTCL Original Investigation Research
jamadermatology.com (Reprinted) JAMA Dermatology December 2018 Volume 154, Number 12 1431
© 2018 American Medical Association. All rights reserved.
